Details of the Drug

General Information of Drug (ID: DMCBJSR)

• Drug Name: Sunitinib
• Synonyms: Sunitanib; Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)

Indication

Disease Entry	ICD 11	Status	REF
Acute undifferentiated leukemia	N.A.	Approved	[1]
Chronic myelomonocytic leukemia	N.A.	Approved	[1]
Classic Kaposi sarcoma	N.A.	Approved	[1]
Gastrointestinal cancer	2C11	Approved	[2]
Gastrointestinal stromal tumour	2B5B	Approved	[3]
Large granular lymphocytic leukemia	2A90.1	Approved	[1]
Lung cancer	2C25.0	Approved	[1]
Mast cell leukaemia	2A21.00	Approved	[1]
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Pancreatic cancer	2C10	Approved	[1]
Primary myelofibrosis	2A20.2	Approved	[1]
Prolymphocytic leukaemia	2A82.1	Approved	[1]
Prostate adenocarcinoma	N.A.	Approved	[1]
Refractory chronic myeloid leukaemia	2A20	Approved	[1]
Salivary gland squamous cell carcinoma	N.A.	Approved	[1]
Plexiform neurofibroma	N.A.	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 398.5
  Logarithm of the Partition Coefficient (xlogp); 2.6
  Rotatable Bond Count (rotbonds); 7
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Clearance: The apparent oral clearance of drug is 34-62 L/h []
  Half-life: The concentration or amount of drug in body reduced by one-half in 40 - 60 hours [4]
  Metabolism: The drug is metabolized via the cytochrome P450 enzyme CYP3A4 []
  Vd: The volume of distribution (Vd) of drug is 2230 L []

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Hypertension	rs4646437	CYP3A4	OTQGYY83	[5]
Vomiting	Not Available	ABCG2 ABCP BCRP BCRP1 MXR	OTW8V2V1	[6]

• Chemical Identifiers:
  Formula: C22H27FN4O2
  IUPAC Name: N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
  Canonical SMILES: CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\\2/C3=C(C=CC(=C3)F)NC2=O)C
  InChI: InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
  InChIKey: WINHZLLDWRZWRT-ATVHPVEESA-N
• Cross-matching ID:
  PubChem CID: 5329102
  ChEBI ID: CHEBI:38940
  CAS Number: 557795-19-4
  DrugBank ID: DB01268
  TTD ID: D0R0MW
  VARIDT ID: DR00454
  INTEDE ID: DR1519
  ACDINA ID: D00646
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Modulator	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
RalBP1-associated Eps domain-containing protein 2 (RALBP1)	DTYEM9B	REPS2_HUMAN	Substrate	[8]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[13]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[13]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)	OTW8V2V1	ABCG2_HUMAN	Drug Response	[6]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Drug Response	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Acute undifferentiated leukemia

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor receptor 2 (KDR)	DTT	KDR	2.27E-01	0.03	0.14
P-glycoprotein 1 (ABCB1)	DTP	P-GP	4.70E-06	-5.80E-02	-1.98E-01
Breast cancer resistance protein (ABCG2)	DTP	BCRP	1.20E-13	-1.20E+00	-1.06E+00
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	4.93E-05	-5.25E-02	-3.14E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	9.49E-02	5.87E-03	5.86E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	1.69E-01	2.37E-02	2.14E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	7.29E-03	-3.47E-02	-1.80E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Sunitinib

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Sunitinib and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[14]

Coadministration of a Drug Treating the Disease Different from Sunitinib (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Sunitinib and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[15]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Sunitinib caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[15]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-glulisine.	Acute diabete complication [5A2Y]	[16]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-aspart.	Acute diabete complication [5A2Y]	[17]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Ivosidenib.	Acute myeloid leukaemia [2A60]	[18]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Midostaurin.	Acute myeloid leukaemia [2A60]	[19]
Arn-509	DMT81LZ	Major	Increased metabolism of Sunitinib caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Oliceridine.	Acute pain [MG31]	[19]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Dronedarone.	Angina pectoris [BA40]	[19]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[21]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Levalbuterol.	Asthma [CA23]	[22]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Pirbuterol.	Asthma [CA23]	[23]
Oritavancin	DM28D05	Moderate	Increased metabolism of Sunitinib caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Sunitinib caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Retigabine.	Behcet disease [4A62]	[19]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Sunitinib and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[24]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Eribulin.	Breast cancer [2C60-2C6Y]	[19]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Sunitinib caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Bosutinib.	Breast cancer [2C60-2C6Y]	[14]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[25]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[22]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Probucol.	Coronary atherosclerosis [BA80]	[19]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Pasireotide.	Cushing syndrome [5A70]	[19]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Osilodrostat.	Cushing syndrome [5A70]	[19]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Sunitinib caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[15]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Deutetrabenazine.	Dystonic disorder [8A02]	[26]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Sunitinib and Ingrezza.	Dystonic disorder [8A02]	[27]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Sunitinib caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Sunitinib caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Sunitinib caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Sunitinib caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Sunitinib and Cannabidiol.	Epileptic encephalopathy [8A62]	[14]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Sunitinib caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[15]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Solifenacin.	Functional bladder disorder [GC50]	[19]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Sunitinib caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[19]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Sunitinib caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Sunitinib and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[28]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Sunitinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Sunitinib caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Sunitinib caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Sunitinib and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[30]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Sunitinib and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[19]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Sunitinib and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[31]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Sunitinib caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[15]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Sunitinib caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[32]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Sunitinib caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[14]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Phenolphthalein.	Irritable bowel syndrome [DD91]	[19]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Sunitinib caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[15]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Crizotinib.	Lung cancer [2C25]	[33]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Sunitinib caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Ceritinib.	Lung cancer [2C25]	[19]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Sunitinib caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Osimertinib.	Lung cancer [2C25]	[34]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Selpercatinib.	Lung cancer [2C25]	[14]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Lumefantrine.	Malaria [1F40-1F45]	[15]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Hydroxychloroquine.	Malaria [1F40-1F45]	[35]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[14]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Sunitinib and Idelalisib.	Mature B-cell leukaemia [2A82]	[36]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Sunitinib caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Vemurafenib.	Melanoma [2C30]	[19]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and LGX818.	Melanoma [2C30]	[38]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Sunitinib caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Exjade	DMHPRWG	Moderate	Increased metabolism of Sunitinib caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[15]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Panobinostat.	Multiple myeloma [2A83]	[39]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Fingolimod.	Multiple sclerosis [8A40]	[19]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Sunitinib and Ozanimod.	Multiple sclerosis [8A40]	[40]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Romidepsin.	Mycosis fungoides [2B01]	[19]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Sunitinib caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[14]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Nilotinib.	Myeloproliferative neoplasm [2A20]	[19]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Lofexidine.	Opioid use disorder [6C43]	[19]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Rucaparib.	Ovarian cancer [2C73]	[19]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Triclabendazole.	Parasitic worm infestation [1F90]	[19]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Pimavanserin.	Parkinsonism [8A00]	[41]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Sunitinib caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[42]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[43]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Lefamulin.	Pneumonia [CA40]	[44]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Sunitinib caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[15]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Degarelix.	Prostate cancer [2C82]	[14]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and ABIRATERONE.	Prostate cancer [2C82]	[14]
Enzalutamide	DMGL19D	Major	Increased metabolism of Sunitinib caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[15]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Relugolix.	Prostate cancer [2C82]	[14]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Levomepromazine.	Psychotic disorder [6A20-6A25]	[19]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Iloperidone.	Schizophrenia [6A20]	[19]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Amisulpride.	Schizophrenia [6A20]	[45]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Asenapine.	Schizophrenia [6A20]	[19]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Sunitinib caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[15]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Sunitinib caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Sunitinib and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Armodafinil	DMGB035	Moderate	Increased metabolism of Sunitinib caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Sunitinib and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[19]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[19]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[14]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Pitolisant.	Somnolence [MG42]	[19]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[19]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Sunitinib due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[46]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Sunitinib and Lenvatinib.	Thyroid cancer [2D10]	[19]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Sunitinib and Cabozantinib.	Thyroid cancer [2D10]	[14]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Sunitinib and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[16]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Sunitinib and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[16]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Sunitinib caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium hydroxide	E00234	14798	Alkalizing agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Sunitinib 25 mg capsule	25 mg	Oral Capsule	Oral
Sunitinib 37.5 mg capsule	37.5 mg	Oral Capsule	Oral
Sunitinib 50 mg capsule	50 mg	Oral Capsule	Oral
Sunitinib 12.5 mg capsule	12.5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Sunitinib FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5713).
• [3] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma. Pharmacogenomics J. 2017 Jan;17(1):42-46. doi: 10.1038/tpj.2015.100. Epub 2016 Jan 26.
• [6] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [7] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [8] Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
• [9] Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
• [10] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [11] Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9.
• [12] In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9.
• [13] Drug Interactions Flockhart Table
• [14] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
• [17] Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
• [18] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [19] Canadian Pharmacists Association.
• [20] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [21] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [22] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [23] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [24] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [25] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [26] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [27] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [28] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [29] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [30] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [31] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [32] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [33] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [34] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [35] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [36] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [37] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [38] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [39] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [40] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [41] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [42] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [43] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [44] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [45] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [46] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.